Table 3.
Recent clinical trials designed to investigate the role of anti PD1/PDL1 monoclonal antibodies in association with other immunomodulatory therapies in PDAC treatment.
| Drug Name | Immunomodulator Combination | Mechanism of Action | NCT No. | Phase | Additional Agents |
|---|---|---|---|---|---|
| Anti-PD1 | |||||
| Pembrolizumab | BL-8040 | CXCR4 antagonist | NCT02907099 | II | |
| BL-8040 | CXCR4 antagonist | NCT02826486 | II | ||
| Olaptesed Pegol | CXCL12 antagonist | NCT03168139 | I/II | ||
| Epacadostat | IDO1 inhibitor | NCT03006302 | II | CRS-207, CY/GVAX | |
| Young TIL | Tumor Infiltrating Lymphocytes | NCT01174121 | II | ||
| Nivolumab | Ipilimumab | CLTA-4 blockers | NCT01928394 | I/II | |
| Ipilimumab | CLTA-4 blockers | NCT02866383 | II | RT | |
| Lirilumab | KIR2DL1/2/3 inhibitors | NCT01714739 | I/II | Ipilimumab | |
| Cabiralizumab | CSF1R inhibitor | NCT03336216 | II | Chemotherapy | |
| APX005M | CD40 agonist | NCT03214250 | Ib/II | GnP | |
| CY/GVAX | Recombinant Vaccine | NCT02243371 | II | CRS-207 | |
| Anti-PDL1 | |||||
| Durvalumab | Pexidartinib | CSF1R inhibitor | NCT02777710 | I | |
| Galunisertib | TGFβ inhibitor | NCT02734160 | I | ||
| Oleclumab | 5′-Nucleotidase inhibitor | NCT03611556 | I/II | Chemotherapy | |
| Avelumab | Binimetinib | MEK inhibitor | NCT03637491 | II | Talazoparib |
PD1: Programmed cell death protein 1; PDL-1: Programmed cell death-Ligand 1; CXCR4: CXC chemokine receptor 4; IDO1: indoleamine 2,3-dioxygenase; CLTA-4: Cytotoxic T-lymphocyte-associated-protein 4; KIR2DL1/2/3: Killer cell Ig-like receptor; CSF1R: colony stimulating factor 1 receptor; CD40: Cluster of differentiation 40; TGFβ: Transforming growth factor beta; MEK: Mitogen activated Protein Kinase.